Advisory Panels, Not FDA, Are Most Affected By Rx Safety Concerns – Gottlieb
Executive Summary
The prominent concerns over FDA's drug safety oversight may be impacting advisory committees more than the agency itself, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb suggested
You may also be interested in...
FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency
FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency
Negative Arcoxia Review May Reflect Increasingly High Hurdle For Me-Toos
The Arthritis Drugs Advisory Committee's negative review of Merck's Arcoxia could be more indicative of the increasingly challenging regulatory environment for "me too" products than concerns over the Vioxx follow-on's safety profile